• GW 4869: Proving Exosome Causality in Osteogenesis

  2026-08-13

  GW 4869 hydrochloride hydrate offers a mechanism-first way to test whether lithium-engineered BMSC exosomes, rather than soluble factors alone, drive Wnt10a-dependent osteogenesis. This thought-leadership guide connects neutral sphingomyelinase, ceramide biology, extracellular vesicle release, and translational study design.

• ML365 Workflows for TASK1 and Neuroinflammation

  2026-08-12

  ML365 combines nanomolar TASK1 inhibition with orthogonal assay performance, making it useful for ion-channel target validation and neuroinflammation studies. This guide translates the aged-mouse postoperative cognitive impairment findings into practical assay workflows, controls, and troubleshooting decisions.

• PNU 74654: Translating Wnt Biology into Insight

  2026-08-12

  PNU 74654 is a research-focused Wnt signaling pathway inhibitor for dissecting β-catenin biology, cell fate, cancer research, and stem cell research. This thought-leadership guide connects mechanistic evidence with practical validation and translational strategy.

• Quercetin, Hippo Signaling, and Cataract

  2026-08-11

  A 2025 study links quercetin-mediated lens protection to suppression of Hippo signaling, improved antioxidant status, and greater survival of lens epithelial cells. Its combined network-pharmacology, UVB-induced cataract, and hydrogen-peroxide injury models provide a mechanistic framework for evaluating non-surgical cataract interventions, while pharmacological pathway reversal highlights important limits to causal interpretation.

• Barley Leaf Senescence Reveals Cathepsin B/L Activity

  2026-08-11

  Schepetkin and Fischer combined substrate profiling, pH-response analysis, inhibitor pharmacology, activity-based labeling, and immunoblotting to characterize cysteine proteases during developmental senescence in barley leaves. Their results connect declining Rubisco abundance and protein content with increased cathepsin B- and L-like activity, while showing why CA-074 responses in plant extracts should not be interpreted as a standalone identification of cathepsin B.

• WNT5a/GSK3/β-Catenin Controls FAP Adipogenesis

  2026-08-10

  The reference study identifies the WNT5a/GSK3/β-catenin axis as a key regulator of adipogenic fate in skeletal-muscle fibro/adipogenic progenitors (FAPs). By integrating pharmacology, mass cytometry, transcriptomics, and network modeling, it shows that GSK3 blockade suppresses FAP adipogenesis and supports muscle regeneration-related activity.

• MMP7, EMT, and β-Catenin in Biliary Atresia Fibrosis

  2026-08-09

  The reference study identifies MMP7 as a mechanistic driver of liver fibrosis in biliary atresia, linking E-cadherin cleavage to β-catenin nuclear translocation and epithelial–mesenchymal transition. Its combined clinical, bioinformatic, cellular, and mouse-model evidence supports MMP7 blockade as an antifibrotic strategy while clarifying how β-catenin regulation may be investigated in follow-up studies.

• CCK8 Workflow for Cancer Cell Viability Studies

  2026-08-08

  Use cck8 to build a practical, quantitative workflow for cell viability, proliferation, and treatment-response studies. This guide shows how to apply Cell Counting Kit-8 alongside phagocytosis, immunogenic cell death, and extracellular-matrix assays in oral squamous cell carcinoma research without confusing metabolic readouts with direct cell counts.

• WNT5a/GSK3/β-Catenin Controls FAP Adipogenesis

  2026-08-07

  The reference study identifies the WNT5a/GSK3/β-catenin axis as a regulatory circuit that limits adipogenic conversion of skeletal muscle fibro/adipogenic progenitors (FAPs). By combining pharmacology, mass cytometry, transcriptomics, and network modeling, the authors connect β-catenin stabilization with reduced PPARγ expression, lower muscle fat infiltration, and improved support of satellite-cell differentiation.

• TG003 Cdc2-like Kinase Inhibitor: Optimizing Splicing Assays

  2026-08-07

  TG003 stands out as a nanomolar-potent, selective Cdc2-like kinase inhibitor that empowers researchers to dissect alternative splicing mechanisms and model therapeutic interventions, including exon-skipping and platinum resistance. This guide delivers actionable protocols, troubleshooting insight, and strategic context for advanced Clk inhibition workflows.

• Icatibant in Viral Infections: Clinical Evidence and Researc

  2026-08-06

  The referenced study evaluates the use of icatibant, a bradykinin receptor antagonist, in severe viral infections, notably hantavirus-induced nephropathia epidemica and COVID-19. Its findings highlight the therapeutic rationale and real-world outcomes of KKS modulation, but also underscore the need for controlled studies to clarify timing and efficacy in broader viral syndromes.

• Torin2: Advancing mTOR Inhibitor Strategy in Cancer Research

  2026-08-06

  This thought-leadership article explores how Torin2, a next-generation mTOR inhibitor from APExBIO, is redefining translational oncology by enabling precise dissection of the PI3K/Akt/mTOR pathway. Blending mechanistic insight with strategic experimental guidance, the article discusses Torin2’s molecular specificity, its application in apoptosis and medullary thyroid carcinoma models, and how it empowers researchers to bridge mechanistic discovery with actionable translational workflows. Drawing on recent evidence—including non-canonical apoptosis triggered by RNA Pol II degradation—the piece positions Torin2 as a cornerstone for the next era of cancer research, expanding far beyond conventional product literature.

• Baicalin Restores Visual Cortex Plasticity in Adult Amblyopi

  2026-08-05

  The reference study demonstrates that baicalin, a flavone glycoside from Scutellaria baicalensis, reactivates ocular dominance plasticity and restores visual acuity in adult mice with amblyopia. These findings offer mechanistic insight and identify baicalin as a promising candidate for research on adult neuroplasticity and potential pharmacological intervention in vision disorders.

• Intravesical p21 mRNA-LNP Therapy Suppresses Bladder Tumors

  2026-08-05

  This study introduces a localized, non-viral strategy for bladder cancer using intravesical delivery of p21 mRNA encapsulated in lipid nanoparticles (LNPs). The approach leads to robust suppression of tumor growth and restoration of p21 expression, establishing a clinically relevant model for mRNA-based tumor suppressor replacement therapies.

• Leveraging 2'3'-cGAMP (sodium salt) in STING Pathway Assays

  2026-08-04

  2'3'-cGAMP (sodium salt) enables reliable activation of STING-mediated innate immune responses in diverse cell types, offering a superior alternative for probing type I interferon induction and SASP regulation. This guide details optimized workflows, troubleshooting insights, and translational use-cases that set this APExBIO reagent apart for immunology and cancer research.

551 records 8/37 page Previous Next First page 上5页 678910 下5页 Last page